We have located links that may give you full text access.
CLINICAL TRIAL
JOURNAL ARTICLE
Long-term results after arthroscopic treatment of synovial chondromatosis of the shoulder.
Arthroscopy 2008 March
PURPOSE: The purpose of this study was to document the results of arthroscopic treatment for synovial chondromatosis of the shoulder with loose body removal and partial synovectomy.
METHODS: Five cases of shoulder arthroscopy performed for synovial chondromatosis were reviewed. Removal of loose bodies and partial synovectomy was performed in all cases. Follow-up of 4 to 9 years was obtained on these 5 patients.
RESULTS: The clinical result was very good for all patients. Radiologic signs of chondroma were observed in two patients. Revision surgery was not necessary in either case.
CONCLUSIONS: The clinical results referring to the Constant and Murley score and subjective assessment were very good at 4 to 9 years following surgery. However, in two out of five subjects, radiographs revealed evidence of persisting or recurrent synovial chondroma at follow-up.
LEVEL OF EVIDENCE: Level IV, therapeutic case series.
METHODS: Five cases of shoulder arthroscopy performed for synovial chondromatosis were reviewed. Removal of loose bodies and partial synovectomy was performed in all cases. Follow-up of 4 to 9 years was obtained on these 5 patients.
RESULTS: The clinical result was very good for all patients. Radiologic signs of chondroma were observed in two patients. Revision surgery was not necessary in either case.
CONCLUSIONS: The clinical results referring to the Constant and Murley score and subjective assessment were very good at 4 to 9 years following surgery. However, in two out of five subjects, radiographs revealed evidence of persisting or recurrent synovial chondroma at follow-up.
LEVEL OF EVIDENCE: Level IV, therapeutic case series.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app